The Journal of Allergy and Clinical Immunology
Volume 121, Issue 2 , Pages 326-330 , February 2008

Adiponectin and inflammation: Consensus and controversy

  • Giamila Fantuzzi, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Giamila Fantuzzi, PhD, Department of Kinesiology and Nutrition, University of Illinois at Chicago, 1919 W Taylor Street MC517, Chicago, IL 60612.

Received 15 August 2007 ,Revised 3 October 2007 ,Accepted 5 October 2007.

References 

  1. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007;18:263–270
  2. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380:24–30
  3. Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scholmerich J, et al. Adipocytokines in synovial fluid. JAMA. 2003;290:1709–1710
  4. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1198–1201
  5. Senolt L, Pavelka K, Housa D, Huluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 2006;35:247–252
  6. Chen T-H, Chen L, Hsieh M-S, Chang C-P, Chou D-T, Tsai S-H. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta. 2006;1762:711–718
  7. Ehling A, Schaffler A, Herfarth H, Tarner I, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol. 2006;176:4468–4478
  8. Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006;33:1545–1552
  9. Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int. 2005;68:1825–1833
  10. Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut. 2005;54:789–796
  11. Paul G, Schaffler A, Neumeier M, Furst A, Bataille F, Buechler C, et al. Profiling adipocytokine secretion from creeping fat from Crohn's disease. Inflamm Bowel Dis. 2006;12:471–477
  12. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Reg Peptides. 2006;134:105–113
  13. Fayad R, Pini M, Sennello JA, Cabay RJ, Chan L, Xu A, et al. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology. 2007;132:601–614
  14. Nishihara T, Matsuda M, Araki H, Oshima K, Kihara S, Funahashi T, et al. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology. 2006;131:853–861
  15. Perseghin G, Lattuada G, Danna M, Piceni Sereni L, Maffi P, De Cobelli F, et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab. 2003;285:E1174–E1181
  16. Furuta M, Tamai M, Hanabusa T, Yamamoto Y, Nanjo K, Sanke T. Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients. Diabetes Res Clin Pract. 2006;72:302–307
  17. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins. Exp Clin Endocrinol Diabetes. 2006;114:295–300
  18. Hadjadj S, Aubert R, Fumeron F, Pean F, Tichet J, Roussel R, et al. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia. 2005;48:1088–1092
  19. Shore SA, Terry RD, Flynt L, Xu A, Hug C. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2006;118:389–395
  20. Rothenbacher D, Weyermann M, Fantuzzi G, Brenner H. Adipokines in cord blood and risk of wheezing disorders within the first two years of life. Clin Exp Allergy. 2007;37:1143–1149
  21. Moriconi N, Kraenzlin M, Muller B, Keller U, Nusbaumer CP, Stohr S, et al. Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J Clin Endocrinol Metab. 2006;91:1586–1590
  22. Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, et al. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 2007;33:213–219
  23. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92:2272–2279
  24. Keller P, Moller K, Krabbe KS, Pedersen BK. Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol. 2003;134:107–110
  25. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023–1033
  26. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007;293:E1118–E1128
  27. Behre CJ. Adiponectin: saving the starved and the overfed. Med Hypotheses. 2007;69:1290–1292
  28. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007;6:55–68
  29. Yamauchi T, Ni Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13:332–339
  30. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007;117:375–386

 Supported by National Institutes of Health grants DK061483 and DK068035.

 Disclosure of potential conflict of interest: The author has declared that she has no conflict of interest.

PII: S0091-6749(07)01961-6

doi: 10.1016/j.jaci.2007.10.018

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 2 , Pages 326-330 , February 2008

Article Tools

* Image Usage & Resolution